Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie W Lees

Showing results (41-50 of 96) with videos related to

Pageof 10
Sort By:
Journal of Crohn'S & Colitis|August 16, 2023
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus RecommendationsStefan Schreiber, Silvio Danese, Axel Dignass, et al.
Journal of Crohn'S & Colitis|October 29, 2020
The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal InflammationAndrew Nelson, Christopher J Stewart, Nicholas A Kennedy, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Gut|July 14, 2019
IBD prevalence in Lothian, Scotland, derived by capture-recapture methodologyGareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, et al.
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
The Lancet. Gastroenterology & Hepatology|April 19, 2024
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort studyNeil Chanchlani, Simeng Lin, Claire Bewshea, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|June 16, 2025
Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, ScotlandAlexander T Elford, Nathan Constantine-Cooke, Phil W Jenkinson, et al.
Pageof 10

Showing results (41-50 of 96) with videos related to

Sort By:
Pageof 10
Journal of Crohn'S & Colitis|August 16, 2023
Defining Comprehensive Disease Control for Use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus RecommendationsStefan Schreiber, Silvio Danese, Axel Dignass, et al.
Journal of Crohn'S & Colitis|October 29, 2020
The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal InflammationAndrew Nelson, Christopher J Stewart, Nicholas A Kennedy, et al.
Digestive Diseases and Sciences|December 12, 2018
Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World OutcomesNikolas Plevris, Gareth R Jones, Philip W Jenkinson, et al.
Inflammatory Bowel Diseases|October 19, 2018
Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic RemissionNikolas Plevris, Mathew Lyons, Philip W Jenkinson, et al.
Gut|July 14, 2019
IBD prevalence in Lothian, Scotland, derived by capture-recapture methodologyGareth-Rhys Jones, Mathew Lyons, Nikolas Plevris, et al.
United European Gastroenterology Journal|August 19, 2020
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort studyNathaniel Aviv Cohen, Nikolas Plevris, Uri Kopylov, et al.
The Lancet. Gastroenterology & Hepatology|April 19, 2024
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort studyNeil Chanchlani, Simeng Lin, Claire Bewshea, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysisMathew Lyons, Lauranne A A P Derikx, James Fulforth, et al.
Journal of Crohn'S & Colitis|June 5, 2021
Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational CohortsLauranne A A P Derikx, Heather W Dolby, Nikolas Plevris, et al.
Alimentary Pharmacology & Therapeutics|June 16, 2025
Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, ScotlandAlexander T Elford, Nathan Constantine-Cooke, Phil W Jenkinson, et al.
Pageof 10